FORA Capital LLC Purchases 1,277 Shares of Hologic, Inc. (NASDAQ:HOLX)

FORA Capital LLC raised its position in Hologic, Inc. (NASDAQ:HOLX) by 13.5% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 10,730 shares of the medical equipment provider’s stock after purchasing an additional 1,277 shares during the period. FORA Capital LLC’s holdings in Hologic were worth $874,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. Janus Henderson Group PLC boosted its holdings in Hologic by 29.5% in the 1st quarter. Janus Henderson Group PLC now owns 99,707 shares of the medical equipment provider’s stock valued at $7,773,000 after purchasing an additional 22,732 shares during the period. B. Riley Wealth Advisors Inc. boosted its stake in shares of Hologic by 13.0% in the first quarter. B. Riley Wealth Advisors Inc. now owns 3,198 shares of the medical equipment provider’s stock valued at $249,000 after buying an additional 367 shares during the period. Tidal Investments LLC grew its position in Hologic by 10.8% during the first quarter. Tidal Investments LLC now owns 16,901 shares of the medical equipment provider’s stock worth $1,317,000 after buying an additional 1,654 shares in the last quarter. Comerica Bank grew its position in Hologic by 40.9% during the first quarter. Comerica Bank now owns 110,053 shares of the medical equipment provider’s stock worth $8,580,000 after buying an additional 31,967 shares in the last quarter. Finally, iA Global Asset Management Inc. acquired a new position in Hologic in the 1st quarter valued at $37,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Needham & Company LLC reissued a “buy” rating and set a $90.00 target price on shares of Hologic in a report on Tuesday, October 15th. UBS Group increased their price objective on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Evercore ISI raised their target price on shares of Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a report on Tuesday, October 1st. Citigroup downgraded shares of Hologic from a “buy” rating to a “neutral” rating and cut their price target for the stock from $95.00 to $85.00 in a report on Tuesday, October 1st. Finally, Leerink Partners decreased their price objective on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Hologic has an average rating of “Moderate Buy” and an average price target of $89.91.

Hologic Stock Up 0.6 %

Shares of HOLX opened at $79.44 on Friday. Hologic, Inc. has a 52 week low of $67.59 and a 52 week high of $84.67. The stock has a fifty day moving average of $80.28 and a 200-day moving average of $78.42. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. The stock has a market capitalization of $18.45 billion, a price-to-earnings ratio of 23.86, a PEG ratio of 2.51 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last posted its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. During the same period last year, the company earned $0.89 EPS. The firm’s revenue was up 4.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Hologic, Inc. will post 4.27 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.